Core Viewpoint - LakeShore Biopharma has received a revised non-binding proposal from a consortium to acquire all outstanding ordinary shares at a price of US$0.86 per share, which is unchanged from the original proposal [1][2]. Group 1: Proposal Details - The consortium, consisting of Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc., aims to acquire all ordinary shares not currently owned by them in an all-cash transaction [1][11]. - The consortium currently owns approximately 52.1% of the Company's issued and outstanding ordinary shares and has agreed to vote in favor of the proposed transaction [3][12]. - The proposal remains unchanged from the original offer made on August 18, 2025, and the consortium has committed to not support any competing bids while they remain members [2][15]. Group 2: Board and Committee Actions - The Company has formed a special committee of three independent directors to evaluate the revised proposal and the proposed transaction, with Adam Zhao serving as the chair [4]. - The special committee will retain independent legal and financial advisors to assist in its review of the proposal [12]. Group 3: Company Background - LakeShore Biopharma, formerly known as YS Biopharma, is focused on developing vaccines and therapeutic biologics for infectious diseases and cancer, utilizing its proprietary PIKA® immunomodulating technology platform [6]. - The Company operates in China, Singapore, and the Philippines, and is led by a management team with extensive experience in the biopharmaceutical industry [6].

Core Viewpoint - LakeShore Biopharma has received a preliminary non-binding proposal from Oceanpine Capital to acquire all outstanding ordinary shares at a price of US$0.86 per share, representing a premium over recent trading prices [1][2][10]. Group 1: Proposal Details - The proposed purchase price of US$0.86 per Ordinary Share represents a premium of 10.3% to the last closing price on August 15, 2025, and an 11.4% premium to the average closing price over the last 15 trading days [2][10]. - Oceanpine Capital plans to fund the transaction using rollover equity and available cash, ensuring that the proposal is not subject to a financing condition [2][11]. - Oceanpine Capital has engaged White & Case LLP as its international legal advisor for the proposed transaction [2][12]. Group 2: Company Background - LakeShore Biopharma is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer, utilizing its proprietary PIKA® immunomodulating technology platform [5]. - The company operates in China, Singapore, and the Philippines, led by a management team with extensive local and global experience in the biopharmaceutical industry [5]. Group 3: Board's Response - The Board of LakeShore Biopharma has just received the proposal and will review it to determine the best course of action for the company and its shareholders [3][4].